No Data
Zhejiang Hisun Pharmaceutical Co., Ltd. 2024 Annual Report
Summary of the 2024 Annual Report of Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical (600267.SH): Net income of 0.6 billion yuan in 2024.
On March 28, GELONGHUI reported that Zhejiang Hisun Pharmaceutical (600267.SH) announced its annual report for 2024, achieving revenue of 9.787 billion yuan, a year-on-year decrease of 5.65%; net income attributable to shareholders of the listed company was 0.6 billion yuan; and basic EPS was 0.52 yuan. It is proposed to distribute cash of 2.10 yuan (including tax) for every 10 shares to all shareholders.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Overview of the lifting of restrictions on the tradability of A-shares | February 24.
According to the Zhitong Finance App, on February 24, 20 listed companies had their restricted shares unlocked, with a total market value of approximately 10.741 billion yuan. The specific situation of the restricted shares unlocked today is as follows: Stock Abbreviation Stock Code Restricted Stock Type Unlocked Shares Luzhou Laojiao 000568 Stock-based Incentive 2.051 million Xiamen Xinde Co Ltd. 000701 Stock-based Incentive 0.172 million Shanzi Gaoke 000981 Other 2.988 billion YANKUANG ENERGY 600188 Stock-based Incentive 29.2178 million Anhui Tongfeng Electronics 600237 Additional issuance of A shares allocated to legal persons 17.192 million Zhejiang Hisun Pharmaceutical 60
Zhejiang Hisun Pharmaceutical (600267.SH): The DeepSeek-R1 model has been integrated into HisunAI.
On February 14, Gelonghui reported that Zhejiang Hisun Pharmaceutical (600267.SH) stated on the investor interaction platform that the DeepSeek-R1 model has been integrated with Zhejiang Hisun Pharmaceutical's Hisun AI. The company's IT department will organize training to Share insights on DeepSeek interpretation and practical AI skills. Furthermore, the company highly recognizes the empowering potential of AI technology for future industrial development, and hopes to leverage strategic cooperation with AI pharmaceutical companies to facilitate breakthroughs in new drug research and development by overcoming technological barriers and advancing the application of AI in the drug development phase. On the other hand, the company is also striving to build a team by introducing high-level talents from the AI field.
Benign Growth For Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) Underpins Stock's 27% Plummet
